CompletedPhase 3

Linagliptin Versus Placebo in Type 2 Diabetic Patients With Inadequate Glycaemic Control on Metformin in Combination With Pioglitazone

NCT00996658

What is this trial?

Generating plain-language summary...

Am I eligible?

Generating eligibility summary...

What's involved?

Summarizing study design...

Where and how to apply

Primary location

1218.61.01028 Boehringer Ingelheim Investigational Site

Escondido, California, United States

+51 additional locations

View on ClinicalTrials.gov

Save this trial

Quick facts

Start date: 2009-10
Enrollment: 278 participants
Sponsor: Boehringer Ingelheim
Purpose: treatment

Locations (52)

1218.61.01028 Boehringer Ingelheim Investigational SiteEscondido, California, United States
1218.61.01014 Boehringer Ingelheim Investigational SiteGreenbrae, California, United States
1218.61.01015 Boehringer Ingelheim Investigational SiteLos Angeles, California, United States
1218.61.01042 Boehringer Ingelheim Investigational SiteParamount, California, United States
1218.61.01046 Boehringer Ingelheim Investigational SitePoway, California, United States
1218.61.01044 Boehringer Ingelheim Investigational SiteSan Diego, California, United States
1218.61.01009 Boehringer Ingelheim Investigational SiteMiami, Florida, United States
1218.61.01049 Boehringer Ingelheim Investigational SiteLawrenceville, Georgia, United States
1218.61.01008 Boehringer Ingelheim Investigational SiteRoswell, Georgia, United States
1218.61.01040 Boehringer Ingelheim Investigational SiteMeridian, Idaho, United States
1218.61.01016 Boehringer Ingelheim Investigational SiteChicago, Illinois, United States
1218.61.01018 Boehringer Ingelheim Investigational SiteChicago, Illinois, United States
1218.61.01048 Boehringer Ingelheim Investigational SiteLafayette, Indiana, United States
1218.61.01001 Boehringer Ingelheim Investigational SiteAuburn, Maine, United States
1218.61.01043 Boehringer Ingelheim Investigational SiteOlive Branch, Mississippi, United States
1218.61.01052 Boehringer Ingelheim Investigational SiteLas Vegas, Nevada, United States
1218.61.01030 Boehringer Ingelheim Investigational SiteNew York, New York, United States
1218.61.01007 Boehringer Ingelheim Investigational SiteGreensboro, North Carolina, United States
1218.61.01004 Boehringer Ingelheim Investigational SiteJacksonville, North Carolina, United States
1218.61.01023 Boehringer Ingelheim Investigational SiteWilmington, North Carolina, United States
1218.61.01027 Boehringer Ingelheim Investigational SitePerrysburg, Ohio, United States
1218.61.01031 Boehringer Ingelheim Investigational SiteEast Providence, Rhode Island, United States
1218.61.01017 Boehringer Ingelheim Investigational SiteSimpsonville, South Carolina, United States
1218.61.01005 Boehringer Ingelheim Investigational SiteDallas, Texas, United States
1218.61.01006 Boehringer Ingelheim Investigational SiteHouston, Texas, United States
1218.61.01053 Boehringer Ingelheim Investigational SiteSan Antonio, Texas, United States
1218.61.01003 Boehringer Ingelheim Investigational SiteSugar Land, Texas, United States
1218.61.01024 Boehringer Ingelheim Investigational SiteBennington, Vermont, United States
1218.61.01020 Boehringer Ingelheim Investigational SiteSpokane, Washington, United States
1218.61.3301A Boehringer Ingelheim Investigational SiteBesançon, France
1218.61.3306A Boehringer Ingelheim Investigational SiteBéziers, France
1218.61.3311A Boehringer Ingelheim Investigational SiteBéziers, France
1218.61.3309A Boehringer Ingelheim Investigational SiteBourg Des Cptes, France
1218.61.3310A Boehringer Ingelheim Investigational SiteCournonterral, France
1218.61.3312A Boehringer Ingelheim Investigational SiteLaval, France
1218.61.3313A Boehringer Ingelheim Investigational SiteLouvigné-de-Bais, France
1218.61.3305A Boehringer Ingelheim Investigational SiteParis, France
1218.61.3307A Boehringer Ingelheim Investigational SiteParis, France
1218.61.91002 Boehringer Ingelheim Investigational SiteBangalore, India
1218.61.91003 Boehringer Ingelheim Investigational SiteBangalore, India
1218.61.91004 Boehringer Ingelheim Investigational SiteBangalore, India
1218.61.91008 Boehringer Ingelheim Investigational SiteHyderabad, India
1218.61.91009 Boehringer Ingelheim Investigational SiteJaipur, India
1218.61.91010 Boehringer Ingelheim Investigational SiteKarnataka, India
1218.61.91001 Boehringer Ingelheim Investigational SiteMaharashtra, India
1218.61.91006 Boehringer Ingelheim Investigational SiteMaharashtra, India
1218.61.91011 Boehringer Ingelheim Investigational SiteMaharashtra, India
1218.61.91005 Boehringer Ingelheim Investigational SiteMumbai, India
1218.61.91007 Boehringer Ingelheim Investigational SiteMumbai, India
1218.61.63003 Boehringer Ingelheim Investigational SiteCebu City, Philippines
1218.61.63004 Boehringer Ingelheim Investigational SiteCebu City, Philippines
1218.61.63002 Boehringer Ingelheim Investigational SiteDavao City, Philippines